Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study addresses the hypothesis that intermittent treatment with fenretinide intravenous
emulsion will induce objective responses in patients with relapsed or refractory Peripheral
T-cell Lymphoma (PTCL) who have failed at least one prior systemic therapy and will result in
acceptable toxicities.